<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://hdl.handle.net/10884/1446" />
  <subtitle />
  <id>http://hdl.handle.net/10884/1446</id>
  <updated>2026-04-09T07:56:26Z</updated>
  <dc:date>2026-04-09T07:56:26Z</dc:date>
  <entry>
    <title>CSR: a catalyst for corporate contribution to global health governance? A case study from the pharmaceutical industry</title>
    <link rel="alternate" href="http://hdl.handle.net/10884/1454" />
    <author>
      <name>Monachino, Michelle</name>
    </author>
    <author>
      <name>Moreira, J. Paulo</name>
    </author>
    <id>http://hdl.handle.net/10884/1454</id>
    <updated>2019-12-11T03:00:45Z</updated>
    <published>2016-01-01T00:00:00Z</published>
    <summary type="text">Title: CSR: a catalyst for corporate contribution to global health governance? A case study from the pharmaceutical industry
Authors: Monachino, Michelle; Moreira, J. Paulo
Abstract: Over the past twenty years international health and development agencies (WHO,&#xD;
1997, 2005; UN, 2002; World Bank, 2002; WEF, 2011) have gradually advocated&#xD;
towards a participation of the private for-profit sector, and especially large multinational&#xD;
corporations (MNCs), in global population health promotion and disease&#xD;
prevention. Participation has been justified in terms of the socioeconomic agency of&#xD;
corporations in a globalized world, as well as connected to the positive and negative&#xD;
social, environmental and health externalities consequent to business manufacturing,&#xD;
distribution and marketing practices.</summary>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

